دورية أكاديمية
D1 Agonist Improved Movement of Parkinsonian Nonhuman Primates with Limited Dyskinesia Side Effects.
| العنوان: | D1 Agonist Improved Movement of Parkinsonian Nonhuman Primates with Limited Dyskinesia Side Effects. |
|---|---|
| المؤلفون: | Young D, Popiolek M, Trapa P, Fonseca KR, Brevard J; Quanticare , Cambridge , Massachusetts 02139 , United States., Gray DL, Kozak R |
| المصدر: | ACS chemical neuroscience [ACS Chem Neurosci] 2020 Feb 19; Vol. 11 (4), pp. 560-566. Date of Electronic Publication: 2020 Feb 06. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Chemical Society Country of Publication: United States NLM ID: 101525337 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1948-7193 (Electronic) Linking ISSN: 19487193 NLM ISO Abbreviation: ACS Chem Neurosci Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Washington, D.C. : American Chemical Society |
| مواضيع طبية MeSH: | Dopamine Agonists/*pharmacology , Motor Activity/*drug effects , Neurodegenerative Diseases/*drug therapy , Parkinsonian Disorders/*drug therapy, Animals ; Antiparkinson Agents/pharmacology ; Corpus Striatum/drug effects ; Dopamine/pharmacology ; Dyskinesia, Drug-Induced/drug therapy ; Oxidopamine/pharmacology ; Parkinson Disease/drug therapy ; Rats |
| مستخلص: | Parkinson's disease is a progressive neurodegenerative disease characterized by striatal dopaminergic loss. L-DOPA treatment replaces lost dopamine and enables motor function; however, eventually, fluctuating efficacy and side effects associated with its use become challenging for many patients. Here, we demonstrate, in a clinically translatable nonhuman primate model of parkinsonian motor symptoms, that treatment with the partial D1 receptor agonist CVL-751, formerly known as PF-06649751, is just as effective as L-DOPA in enabling movement and reducing disability. Importantly, CVL-751 efficacy is observed with less of the concomitant dyskinesia side effect associated with L-DOPA treatment. Data presented suggest that partial D1 agonists may be an effective and important treatment strategy for the management of Parkinson's patients. |
| فهرسة مساهمة: | Keywords: D1 receptor agonist; Parkinson’s disease; dyskinesia; nonhuman primate |
| المشرفين على المادة: | 0 (Antiparkinson Agents) 0 (Dopamine Agonists) 8HW4YBZ748 (Oxidopamine) VTD58H1Z2X (Dopamine) |
| تواريخ الأحداث: | Date Created: 20200124 Date Completed: 20210303 Latest Revision: 20210303 |
| رمز التحديث: | 20221213 |
| DOI: | 10.1021/acschemneuro.9b00589 |
| PMID: | 31971364 |
| قاعدة البيانات: | MEDLINE |
Find this issue from the American Chemical Society | تدمد: | 1948-7193 |
|---|---|
| DOI: | 10.1021/acschemneuro.9b00589 |